MktsMarkets

Galectin Therapeutics Inc.
NASDAQ: GALTKey statistics
GALT News
Stories mentioning GALT from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,231 | 1,933 | 2,611 | 3,261 | 6,485 | 11,109 | 7,595 | 9,813 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 4,077 | 3,365 | 4,198 | 4,625 | 7,897 | 12,428 | 9,066 | 11,291 |
| Operating Income (Loss) | (4,077) | (3,365) | (4,198) | (4,625) | (7,897) | (12,428) | (9,066) | (11,291) |
| Interest Income | 36.00 | 26.00 | 39.00 | 26.00 | 35.00 | 85.00 | 93.00 | 80.00 |
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (5,046) | (5,500) | (8,184) | (7,521) | (9,631) | (11,967) | (11,220) | (12,371) |
| Earnings Per Share (Basic) | (0.08) | (0.09) | (0.13) | (0.12) | (0.15) | (0.19) | (0.18) | (0.20) |
| Earnings Per Share (Diluted) | (0.08) | (0.09) | (0.13) | (0.12) | (0.15) | (0.19) | (0.18) | (0.20) |
| Weighted Average Shares Outstanding (Basic) | 65,782 | 63,903 | 64,205 | 63,447 | 63,204 | 62,309 | 62,278 | 62,233 |
| Weighted Average Shares Outstanding (Diluted) | 65,782 | 63,903 | 64,205 | 63,447 | 63,204 | 62,309 | 62,278 | 62,233 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About GALT
Galectin Therapeutics Inc. (NASDAQ: GALT) is a stock listed on the Nasdaq Stock Market under the ticker symbol GALT. It last traded at $2.69 (Nov 20, 2026, 4:00 PM ET), down 4.3% on the day. That gives Galectin Therapeutics a market capitalisation of $283.5M.
Over the past 52 weeks GALT has traded between $2.02 and $7.13.
For the quarter ended Mar 31, 2026 it reported a net loss of $5.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$5.0M |
| Dec 31, 2025 | — | -$5.5M |
| Sep 30, 2025 | — | -$8.2M |
| Jun 30, 2025 | — | -$7.5M |
From Galectin Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…